SBIR/STTR Research Award
Inhibiting PLEKHA7 for mutant KRAS therapy
Award amount
$225,000Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PHusis Therapeutics Inc
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- JGZFBDAL61C4
- Solicitation number
- PA13-234
- Topic code
- NCI
Research abstract
DESCRIPTION (provided by applicant): Oncogenic KRAS is found in 25% of patient tumors across many cancer types. Despite extensive effort since its discovery over 30 years ago there is still no effective treatment for KRAS tumors. An estimated 350,000 patients in the US in 2013 will be diagnosed with mutated KRAS in their tumor, and many will die of their disease. Mutated KRAS plays a critical role in driving tumor growth and resistance to therapy. Its effects are so powerful that it overrides the activity of many of the new molecularly targeted signaling drugs being developed for cancer. Thus, finding new agents that inhibit the effects of mutated KRAS is one of the most important unmet medical needs in cancer today. Mutated KRAS as a target also presents anuntapped business opportunity because of the large number of patients that could benefit from an effective inhibitor, used alone or in combination with molecularly targeted therapies from which the patients are currently excluded. PHusis Therapeutics
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Clinical evaluation of a novel AKT/PDK1 inhibitor, PHT-427, for the treatment of multi-field actinitc keratoses
- rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
3 SBIR/STTR records share this UEI (2013–2025). Reported award amounts total $2,598,199. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services